Dr. Peter Kelly:

I will make one if the Vice Chair does not mind. I draw people's attention to something members may have come across. The Irish Government's Economic and Evaluation Services carried out a review of labelled and unlabelled expenditure under the national drugs strategy which found that limitations in the availability and quality of data in the performance indicators have constrained the conclusions that can be drawn on the performance of the strategy. There is a massive piece around data collection and measurement, which leads into accountability and stigmatisation. I urge members to prioritise that. It is important.